The use of oral anticoagulants (warfarin) in older people

Journal of the American Geriatrics Society

Volumn 48, Issue 2, 2000, Pages 224-227

  Jacobs, L G ^a   Cefalu, C A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; BLEEDING; CARDIOMYOPATHY; DEEP VEIN THROMBOSIS; DRUG INDICATION; ELDERLY CARE; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART REINFARCTION; HEART VALVE PROSTHESIS; HIGH RISK PATIENT; HUMAN; INTERNATIONAL STANDARD UNIT; LUNG EMBOLISM; MORTALITY; PRACTICE GUIDELINE; REVIEW; STROKE; THROMBOEMBOLISM; VALIDATION PROCESS; VALVULAR HEART DISEASE;

EID: 0033957232     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2000.tb03917.x     Document Type: Review

References (63)

1. Dalen JE, Hirsh J. Fifth ACCP Consensus Conference on Antithrombotic Therapy. Chest 1998;114(suppl):439-769S.
2. Hirsh J, Dalen JE, Deykin D et al. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998: 114(suppl):445-469S.
3. Sevitt S, Gallagher NG. Prevention of venous thrombosis and pulmonary embolism in injured patients. Lancet 1959:2:981-989.
4. Francis CW, Marder VJ, Evarts CM et al. Two-step warfarin therapy: Prevention of postoperative venous thrombosis without excessive bleeding. JAMA 1983;249:374-378.
5. Powers PJ, Gent M, Jary RM et al. A randomized trial of less intensive post-operative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Intern Med 1989;149:771-774.
6. Francis CW, Pellegrini VD Jr, Leibert KM et al. Comparison of two warfarin regimens in the prevention of venous thrombosis following total knee replacement. Thromb Haemost 1996;75:706-711.
7. Taberner DA, Poller L, Burslem RW et al. Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep venous thrombosis. BMJ 1978;1:272-274.
8. Poller L, McKernan A, Thomson JM et al. Fixed minidose warfarin: A new approach to prophylaxis against venous thrombosis after major surgery. BMJ 1987;295:1309-1312.
9. Poller L, MacCallum PK, Thomson JM et al. Reduction of factor VII coagulant activity (VIIC), a double blind crossover study. Br Heart J 1990;63:231-233.
10. Dale C, Callus AS, Wycherley A et al. Prevention of venous thrombosis with minidose warfarin after joint replacement. BMJ 1991;303:224.
11. Fordyce MJF, Baker AS, Staddon GE. Efficacy of fixed minidose warfarin prophylaxis in total hip replacement. BMJ 1991;303:219-220.
12. Hull R, Delmar T, Genton E et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979;302: 855-858.
13. Hull R, Delmore T, Carter C et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982;306:189-194.
14. Callus AS, Jackaman J, Tillet J et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986;2:1293-1296.
15. Langerstedt CI, Fagher BO, Albrechtsson U et al. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985;2:515-518.
16. Huisman MV, Buller HR, ten Cate JW et al. Serial impedance plethysmography for suspected deep venous thrombosis in outpatients: The Amsterdam General Practitioner Study. N Engl J Med 1986;316:823-828.
17. Schulman S, Rhedin AS, Lindmarker P et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995:332:1661-1665.
18. Schulman S, Granqvist S, Holmstrom M et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997;336:393-398.
19. Guidelines on Oral Anticoagulation, 3rd Ed. Br J Haematol 1998;101:374-387.
20. Hull R, Hirsh J, Jay R et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982;307: 1676-1681.
21. The Stroke Prevention in Atrial Fibrillation Investigators. The stroke prevention in atrial fibrillation study: Final results. Circulation 1991;84:527-539.
22. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators, The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990;323:1505-1511.
23. Petersen P, Boysan G, Godtfredsen J et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK study. Lancet 1989;1:175-178.
24. Connolly SJ, Laupacis A, Gent M et al. for the CAFA Study Co-investigators. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349-355.
25. Ezekowitz MD, Bridgeers SL, James KE et al. Warfarin in the prevention of stroke associated with nonrheumaric atrial fibrillation. N Engl J Med 1992; 327:1406-1412.
26. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-1262.
27. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-691.
28. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of anti-thrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457.
29. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-546.
30. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet 1996;348:633-638.
31. Van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy: An analysis of risk factors. Arch Intern Med 1993;153:1557-1562.
32. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995;333:5-10.
33. Fuster V, Gersh B, Giulani E et al. The natural history of dilated cardiomyopathy. J Cardiol 1981;47:525-531.
34. Schecter A, Fuster V, Chesebro J. Anticoagulants in Cardiomyopathy. Oral Anticoagulants. London: Arnold, 1996, pp 258-263
35. Levine H, Pauker S, Eckman MH. Antirhromboric therapy in valvular heart disease. Chest 1995;104:360-370S.
36. Mok CK, Boey J, Wang R et al. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: A prospective clinical trial. Circulation 1985;72:1059-1063.
37. Turpie AGG, Gunstensen J, Hirsh J et al. Randomized comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement, Lancet 1988;1:1242-1245.
38. Saour JN, Sieck JO, Mamo LAR et al. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990;322:428-432.
39. Altman P, Rouvier J, Gurfinkel E et al. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991;101:427-431.
40. Veterans Administration Cooperative Study. Anticoagulants in acute myocardial infarction: Results of a cooperative clinical trial. JAMA 1973;225:724-729.
41. Drapkin A, Mersky C. Anticoagulant therapy after acute myocardial infarction. JAMA 1972;222:541-.548.
42. Cairns JA, Hirsh J, Lewis HD Jr et al. Antithrombotic agents in coronary artery disease. Chest 1992;102:456-481S.
43. Goldberg RJ, Gore JM, Dalen JE et al. Long term anticoagulant therapy after acute myocardial infarction. Am Heart J 198.5;109:616.
44. Leizorovicz A, Boissel JP. Oral anticoagulant in patients surviving myocardial infarction. Eur J Clin Pharmacol 1983;24:333.
45. Sixty-Plus Reinfarction Study Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980;2:989-994.
46. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323:147-151.
47. ASPECT Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardioversion morbidity after myocardial infarction. Lancet 1994;343:499-503.
48. Cairns JA, Lewis HD, Meade TW et al. Antithrombotic agents in coronary artery disease. Chest 1995;104:380-400S.
49. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989;87:144-152.
50. Petitti DB, Strom BL, Melmon KL. Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin. J Clin Epidemiol 1989;42:959-964.
51. Gurwitz JH, Avorn J, Ross-Degnan D et al. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med 1992;116:901-904.
52. Fihn SD, McDonell M, Martin E et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Ann Intern Med 1993;118: 511-520.
53. Redwood M, Taylor C, Bain B, Mathews J. The association of age with dosage requirement for warfarin. Age Aging 1991;20:217-220.
54. O'Malley K, Stevenson IH, Ward CA et al. Determinants of anticoagulant control in patients receiving warfarin. Br J Clin Pharmacol 1977;4:309-314.
55. Shepherd AMM, Hewick DS, Moreland TA, Stevenson IH. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol 1977;4:315-320.
56. Gladman JRF, Dolan G. Effect of age upon the induction and maintenance of anticoagulation with warfarin. Postgrad Med J 1995;71:153-155.
57. Routledge PA, Chapman PH, Davies DM, Rawlins MD. Factors affecting warfarin requirements. Eur J Clin Pharmacol 1979;15:319-322.
58. Palareti G, Leali N, Coccheri S et al. Bleeding complications of oral anticoagulant treatment: An Inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996;348:423-428.
59. Tiede DJ, Nishimura RA, Gastineau DA et al. Modern management of prosthetic valve anticoagulation. Mayo Clin Proc 1998;73:665-680.
60. Tinker JH, Tarhan S. Discontinuing anticoagulant therapy in surgical patients with cardiac valve prostheses: Observations in 180 operations. JAMA 1978;239:738-739.
61. Francis CW, Marder VJ, Evarts CM, Yaukoolbodi S. Two-step warfarin therapy: Prevention of postoperative venous thrombosis without excessive bleeding. JAMA 1983;249:374-378.
62. Glover JJ, Morrill GB. Conservative treatment of overanticoagulated patients. Chest 1995;108:987-990.
63. Madura JA, Rookstool M, Wease G. The management of patients on chronic Coumadin therapy undergoing subsequent surgical procedures. Am Surg 1994;60:542-546.